Formycon Submits Eylea Biosimilar For European Approval Following Strong Q3

Revenue Increased 113% During First Nine Months Of 2023

 
• By Chloe Kent
  
EMA
Aflibercept represents a significant market opportunity for Formycon
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products